Company Enzo Biochem, Inc. BOERSE MUENCHEN

Equities

EZB

US2941001024

Biotechnology & Medical Research

Market Closed - BOERSE MUENCHEN 20:44:02 28/06/2024 BST 5-day change 1st Jan Change
0.995 EUR +2.05% Intraday chart for Enzo Biochem, Inc. -4.41% -21.37%

Business Summary

Enzo Biochem, Inc. is focused on molecular diagnostics and has a portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. The Company operates through the product segment, which manufactures, develops and markets products and tools for clinical research, translational research, drug development and bioscience research customers worldwide. The Company is engaged in product development and manufactures and supplies a comprehensive portfolio of products, including antibodies, genomic probes, assays, biochemicals and proteins. The Company's products and technologies are used in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry and small molecule chemistry. Its life science division supports the work of research centers and industry partners. It has built a portfolio of intellectual property assets, comprised of around 457 owned patents worldwide.

Sales per Business

USD in Million2022Weight2023Weight Delta
Life Sciences Products
100.0 %
33 30.5 % 31 100.0 % -4.85%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
59.7 %
94 88.0 % 19 59.7 % -80.31%
Europe
27.2 %
9 8.0 % 8 27.2 % -1.40%
Asia Pacific
13.1 %
4 4.0 % 4 13.1 % -5.40%

Managers

Managers TitleAgeSince
Chief Executive Officer 56 31/12/10
Founder 81 31/07/76
Director of Finance/CFO 47 -
Chief Tech/Sci/R&D Officer 60 30/06/14

Members of the board

Members of the board TitleAgeSince
Chairman 64 25/10/23
Director/Board Member 58 16/11/20
Director/Board Member 50 02/01/22
Founder 81 31/07/76
Chief Executive Officer 56 31/12/10
Director/Board Member 57 24/11/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 51,457,660 39,064,692 ( 75.92 %) 0 75.92 %

Shareholders

NameEquities%Valuation
Harbert Fund Advisors, Inc.
10.10 %
5,175,913 10.10 % 6 M €
James Wolf
9.648 %
4,942,400 9.648 % 6 M €
4,820,882 9.411 % 6 M €
1 Main Capital Management LLC
4.880 %
2,500,000 4.880 % 3 M €
Renaissance Technologies LLC
4.754 %
2,435,129 4.754 % 3 M €
1,966,998 3.840 % 2 M €
Vanguard Global Advisers LLC
3.663 %
1,876,622 3.663 % 2 M €
Potomac Capital Management, Inc.
2.893 %
1,481,742 2.893 % 2 M €
Tang Capital Management LLC
2.460 %
1,260,013 2.460 % 1 M €
BlackRock Institutional Trust Co. NA
1.735 %
888,789 1.735 % 1 M €

Company contact information

Enzo Biochem, Inc.

81 Executive Boulevard Suite 3

10022, New York

+631 755 5500

http://www.enzo.com
address Enzo Biochem, Inc.(EZB)